anti-CD20.IL21

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-CD20.IL21

Drug Alias Nameanti-CD20-IL-21 fusokine

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionB-lymphocyte antigen CD20 inhibitorsInterleukin-21 stimulants

TargetsB-lymphocyte antigen CD20Interleukin-21

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity Of California

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUniversity Of California

Active IndicationsN/A

Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A